Why the study?
The efficacy and safety of tranexamic acid in noncardiac surgery were uncertain, and whether statins prevent perioperative cardiovascular complications required feasibility assessment for a definitive perioperative trial.
Are perioperative trials of tranexamic acid and rosuvastatin feasible in patients at cardiovascular risk undergoing noncardiac surgery?
Are perioperative trials of tranexamic acid and rosuvastatin feasible in patients at cardiovascular risk undergoing noncardiac surgery?
A pilot study demonstrates that a perioperative tranexamic acid trial in noncardiac surgery is feasible, whereas a rosuvastatin trial faces significant recruitment and compliance challenges.
Answers are grounded in this paper and cite their sources.
TXA perioperative trials feasible in CV-risk noncardiac surgery; challenges rosuvastatin viability due to adherence barriers.
BACKGROUND: Surgical bleeding is associated with postoperative cardiovascular complications. The efficacy and safety of tranexamic acid (TXA) in noncardiac surgery are still uncertain. Statins may prevent perioperative cardiovascular complications. We conducted a pilot to assess the feasibility of a perioperative trial of TXA and rosuvastatin. METHODS: Using a factorial design, we randomized patients at cardiovascular risk undergoing noncardiac surgery to intravenous TXA (1 g at the start and end of surgery) or placebo, and oral rosuvastatin (40 mg before and 20 mg daily for 30 days after surgery) or placebo. Feasibility outcomes included recruitment rates, follow-up, and compliance to interventions. Clinical outcomes were secondarily explored. RESULTS: After 3 months, we changed the design to a partial factorial due to the difficult recruitment of statin-naive patients. Over 6 months, 100 patients were randomized in the TXA trial (49 TXA, 51 placebo), 34 in the rosuvastatin trial (18 rosuvastatin, 16 placebo). Ninety-two percent (95% CI 80-98) of TXA and 86% (95% CI 74-94) of TXA-placebo patients received the 2 study doses. Thirty-three percent (95% CI 13-59) of rosuvastatin patients and 37% (95% CI 15-65) of rosuvastatin-placebo patients discontinued the study drug. A major cardiovascular complication occurred at 30 days in 1 TXA and 6 TXA-placebo patients, and 1 rosuvastatin and no rosuvastatin-placebo patients. CONCLUSIONS: Our pilot study supports the feasibility of a perioperative TXA trial in noncardiac surgery. Feasibility of a perioperative rosuvastatin trial is uncertain because of a high prevalence of statin use in the target population and concerns about compliance. TRIAL REGISTRATION: ClinicalTrials.govNCT02546648.
No takes yet. Share an insight, caveat, or question.
Marcucci et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: